The dystrophic epidermolysis bullosa (DEB) treatment market is witnessing notable growth driven by rising awareness, advancements in gene therapy, and increasing clinical trials focused on rare skin disorders. DEB is a severe and rare genetic skin condition characterized by fragile skin th